[Pancreaticojejunal anastomosis. Indication, technique and results].
Pancreaticojejunal anastomosis. Indication, technique and results. Pancreaticojejunal anastomoses are performed for the treatment of chronic pancreatitis and after resection of pancreatic carcinomas. In chronic pancreatitis by drainage procedures (Partington-Rochelle and Puestow-Gillesby) one can expect good long term results, if the diameter of the pancreatic duct is at least 1 cm and the length of the anastomosis 6 cm. The duodenumpreserving head resection (Beger or Frey) is a combination of resection and drainage and is significant in the therapy of inflammatory head processes. In the surgical treatment of pancreatic carcinomas pancreaticojejunostomies are applied after head resection (Whipple-, pyloruspreserving modification). The end-to-side mucosa-mucosa anastomosis offers the best results concerning postoperativ complications and mortality rates.
Gebhardt
C
C
Klinik für Abdominal, Thorax und Endokrine Chirurgie, Klinikum Nürnberg Nord.
D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004322:Drainage; D006801:Humans; D015337:Multicenter Studies as Topic; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use; D010185:Pancreatic Fistula / Q000209:etiology / Q000517:prevention & control; D010190:Pancreatic Neoplasms / Q000601:surgery*; D010193:Pancreaticojejunostomy / Q000379:methods; D010195:Pancreatitis / Q000401:mortality / Q000601:surgery*; D019512:Pancreatitis, Alcoholic / Q000401:mortality / Q000601:surgery; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D011446:Prospective Studies; D012307:Risk Factors; D015607:Stents; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use
D014662:Vasoconstrictor Agents; D015282:Octreotide